The markets have been on a roll recently, but investors need to stay vigilant and not get complacent, Jim Cramer warned his Mad Money viewers Friday. Stocks may have a tough time next week, depending on how the Federal Reserve responds to these changing market conditions.
Cramer's game plan for next week started on Monday with the planned IPO of co-working space provider WeWork. Cramer said this IPO has him nervous, as the deal has been having trouble finding a price low enough to lure investors. IPOs that go bad can take the rest of the market with them.
On Tuesday, we hear from FedEx (FDX) - Get Report , a company that knows more about the global economy than anyone. We will also hear how the cloud is faring from Adobe Systems (ADBE) - Get Report and whether cybersecurity is slowing down when Zscaler (ZS) - Get Report hosts its analyst day.
Also on Tuesday are the latest industrial production and capacity utilization numbers, which will help set the stage on Wednesday when we will hear from the Fed. Weaker numbers on Tuesday will help justify an interest-rate cut on Wednesday.
Rounding out earnings for the week will be General Mills (GIS) - Get Report on Wednesday and Darden Restaurants (DRI) - Get Report on Thursday. Cramer said he'll be listening to both companies. On Friday, everyone will be waiting to see if President Trump tweets anything regarding trade -- tweets which affect the stock market.
Speaking of Trade and Tariffs...
Before you buy any stock, you need to play a little game, Cramer told viewers. That game is "hostage or not" and it will tell you if your company is hostage to the trade war with China or whether it can be safely bought.
Caterpillar (CAT) - Get Report is not technically hostage to China, Cramer explained, as it derives less than 5% of its revenues from there, but the stock trades on trade news, making it a hostage. The same with Deere & Company (DE) - Get Report , as all agriculture is now tied to China; 3M (MMM) - Get Report and Nvidia (NVDA) - Get Report , as most semiconductors are also tied to tariffs and trade.
Some companies that are not hostage include Bank of America (BAC) - Get Report and Wells Fargo (WFC) - Get Report , both of which are domestic banks. Splunk (SPLK) - Get Report , Workday (WDAY) - Get Report , and the cloud stocks also are not hostage to the global economy because they're driven by secular trends.
Cramer and the AAP team are are adding to a pharmaceutical name in the portfolio, while taking gains in a semiconductor stock. Find out what they're telling their investment club members and get in on the conversation with a free trial subscription to Action Alerts Plus.
Know Your IPO
SmileDirect competes with Align Technologies (ALGN) - Get Report in the invisible orthodontics space, But unlike Align, which requires regular visits to your dentist, SmileDirect allows for at-home impressions of your teeth and virtual check-ins with a dental provider.
Cramer said he likes SmileDirect's accelerating revenues, rising average selling price and the fact the company is trending toward profitability. On the downside however, the stock is expensive at 8.5 times sales at a time when the market values profits, not revenues. He was also worried, as is most of Wall Street, that increased competition may put a damper on profits for both SmileDirect and Align.
In the end, Cramer said he likes SmileDirect, but only if shares fall back to their lows below $16 a share.
On Real Money, Cramer keys in on the companies and CEOs he knows best. Get more of his insights with a free trial subscription to Real Money.
Cramer Does His Homework
In his "Homework" segment, Cramer followed up on a few biotech stocks that had stumped him during earlier shows. He said that biotech is a tricky business and is always speculative. Investors should never gamble with retirement savings, Cramer urged, and only invest with discretionary funds.
Cramer said that Cymabay Therapeutics (CBAY) - Get Report illustrates the potential pitfalls of early-stage biotech. The company had disappointing Phase II trials and the stock plummeted. Iovance Biotherapeutics (IOVA) - Get Report , on the other hand, is worth speculating on, as the company's cancer treatments are promising, Cramer said.
Cramer's big recommendations came with Arrowhead Pharmaceuticals (ARWR) - Get Report and Regenxbio (RGNX) - Get Report , both of which have multiple drugs in development and strong partners to help them cross the finish line.
Continuing his "Homework" segment, Cramer followed up on three more stocks he needed to study. He said that Accelerate Diagnostics (AXDX) - Get Report has failed to deliver on its promises and he cannot recommend it; and TTM Technologies (TTMI) - Get Report is too risky given the company's exposure to China and the trade wars. He was bullish on Medpace Holdings (MEDP) - Get Report however, as the contract research business remains a lucrative one.
Introducing TheStreet Courses: Financial titans Jim Cramer and Robert Powell are bringing their market savvy and investing strategies to you. Learn how to create tax-efficient income, avoid top mistakes, reduce risk and more. With our courses, you will have the tools and knowledge needed to achieve your financial goals. Learn more about TheStreet Courses on investing and personal finance here.
Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.
To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.
To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.
At the time of publication, Cramer's Action Alerts PLUS had a position in CAT, NVDA, NVS.